Search Results
Mar 11, 2026, 08:30 ET U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Mar 11, 2026, 07:41 ET Fractal unveils intelligent sales agents to accelerate B2B growth
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal
Mar 11, 2026, 07:31 ET Fractal unveils intelligent sales agents to accelerate B2B growth
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal
Mar 11, 2026, 07:00 ET Brainomix Deploys AI Imaging Platform Across West Virginia University (WVU) Health System Network to Support Stroke Care
March 11, 2026 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced the deployment of its AI imaging platform, Brainomix 360 Stroke, throughout the West Virginia University (WVU) Health System
More news about: Brainomix
Mar 11, 2026, 06:00 ET New Report Reveals How Community Air Monitoring is Reshaping How Nation Understands, Addresses Air Pollution
2025.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Mar 10, 2026, 15:21 ET Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment Adoption - Credence Research
relevance as a backbone in combination regimens.Non-small cell lung cancer (NSCLC) accounted for the largest application share of 37.0% in 2025, reflecting high immunotherapy penetration and rapid therapy-line sequencing in lung oncology care.Asia Pacific is the fastest-growing region, expected
More news about: Credence Research Inc.
Mar 10, 2026, 11:30 ET Jacobio Announces 2025 Annual Results
HighlightsGlecirasib (KRAS G12C inhibitor)In 2025, glecirasib was approved in China for the treatment of patients with KRAS G12C-mutated non-small cell lung cancer who had received at least one prior systemic therapy, and was subsequently included in the National Reimbursement Drug List. From June to December
More news about: Jacobio Pharma
Mar 10, 2026, 10:00 ET Multi-Organization Partnership Announces $2.5 Million for Aging & Cancer Research
School of Medicine at Mount Sinai)Vera Gorbunova, PhD (University of Rochester)Aging-Associated Inflammation in Lung Cancer EvolutionTuomas Tammela, MD, PhD (Memorial Sloan Kettering Cancer Center)Alexander Tsankov, PhD (Icahn School of Medicine
More news about: The Mark Foundation for Cancer Research
Mar 10, 2026, 09:15 ET New AI Solution Helps Predict Which Lung Cancer Patients Will Benefit from Immunotherapy
CLEVELAND, March 10, 2026 /PRNewswire/ -- Oncologists currently have limited tools to predict which lung cancer patients will benefit from immunotherapy. The
More news about: Picture Health
Mar 10, 2026, 08:30 ET IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Mar 10, 2026, 07:00 ET Genprex to Participate at BIO Europe Spring 2026
Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Genprex, Inc.
Mar 10, 2026, 06:30 ET Setting the Standard for Safer Care: Healthgrades Names 2026 Top Hospitals for Patient Safety
complication and account for 78% of all safety events: In-hospital fall resulting in fracture (52.4% less likely)Collapsed lung due to a procedure or surgery in or around the chest (57.5% less likely)Catheter-related bloodstream infections acquired in the hospital (67.8%
More news about: Healthgrades
Mar 10, 2026, 03:00 ET MemorialCare Saddleback Medical Center Awarded Patient Safety Excellence Award from Healthgrades for Third Year in a Row
non-recipient hospitals, including a lower likelihood of:In-hospital falls resulting in fracture (54% less likely)Collapsed lung due to a procedure or surgery in or around the chest (approximately 55% less likely)Pressure sores or bed sores acquired in the hospital (approximately
More news about: MemorialCare Saddleback Medical Center
Mar 09, 2026, 17:31 ET Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
obscure Notch ligand into a key oncology biomarker, impacting Small Cell Lung Cancer (SCLC), NETs, NEC, including Neuroendocrine Prostate Cancer (NEPC) and Extra-pulmonary NEC (EP-NEC), and Large cell Neuroendocrine Lung Carcinoma (LCNEC). Several companies have advanced gene therapies
More news about: DelveInsight Business Research, LLP
Mar 09, 2026, 08:30 ET American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Mar 09, 2026, 08:30 ET Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Mar 09, 2026, 07:30 ET ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
Authority (SFDA) recently approved ANKTIVA in combination with checkpoint inhibitors for patients with second-line and later metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after standard therapies, including checkpoint inhibitor treatment. In this setting, multiple randomized
More news about: ImmunityBio
Mar 09, 2026, 07:29 ET Rosewood Hotel Group Introduces Global Gender-Neutral Parental Leave Standard of 16 Weeks Fully Paid Leave for Associates Worldwide
reinforcing the Group's commitment to inclusion and equitable opportunity across regions and cultures.Keno Lung, Senior Vice President, Talent and Culture, Global, added: "Our associates are the heart of everything we do. Across hospitality, parenting
More news about: Rosewood Hotel Group
Mar 09, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy agent and
More news about: IDEAYA Biosciences, Inc.
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).The open-label, multi-center Phase Ⅱ clinical study is
More news about: Leads Biolabs
Mar 07, 2026, 10:16 ET U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China
March 7, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China.
More news about: Jiahui International Hospital
Mar 06, 2026, 23:20 ET U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China
March 6, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China.
More news about: Jiahui International Hospital
Mar 06, 2026, 07:00 ET Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S.
high doses or rapid infusion.Hemolysis can develop subsequent to IGIV treatment. Monitor patients for hemolysis.Transfusion-related acute lung injury: Monitor patients for pulmonary adverse reactions.Transmissible infectious agents: QIVIGY is made from human plasma and may carry a risk
More news about: Kedrion Biopharma
Mar 06, 2026, 05:53 ET Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
multiple-ascending-dose (MAD) cohorts, designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adults.Kuo-Lung Huang, Chairman of TaiGen Biotechnology, said, "ISM4808 is an important milestone in TaiGen's drug development strategy. Within 3 months of in-licensing
More news about: Insilico Medicine
Mar 06, 2026, 04:20 ET Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.